Inhibition of tumour necrosis factor alpha in idiopathic membranous nephropathy: a pilot study
Authors:
- 7 February 2009
- journal article
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 24 (7) , 2144-2150
Abstract
Background. Tumour necrosis alpha has been implicated in the pathogenesis of autoimmune disorders was to evaluate the safety, tolerability and potential efficacy of the tumour necrosis factor alpha (TNF-α) inhibitor, etanercept (ET), in patients with idiopathic membranous nephropathy (MN).Keywords
This publication has 61 references indexed in Scilit:
- The influence of genetic variation in the HLA–DRB1 and LTA–TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanerceptArthritis & Rheumatism, 2004
- Pentoxifylline: A potential therapy for chronic kidney diseaseNephrology, 2004
- Pentoxifylline suppresses renal tumour necrosis factor- and ameliorates experimental crescentic glomerulonephritis in ratsNephrology Dialysis Transplantation, 2004
- Alternative therapies and future intervention for treatment of membranous nephropathySeminars in Nephrology, 2003
- Late Expression of Tumor Necrosis Factor-α IS Markedly Depressed in Patients with IGA NephropathyImmunological Investigations, 1998
- Glomerular ICAM-1 Expression Related to Circulating TNF-α in Human GlomerulonephritisNephron, 1997
- Tumor Necrosis Factor: Function, Release and ClearanceCritical Reviews in Immunology, 1996
- Mitogenic effect of platelet-derived growth factor in human glomerular mesangial cells: modulation and/or suppression by inflammatory cytokinesClinical and Experimental Immunology, 1991
- Tumor necrosis factor Characterization at the molecular, cellular and in vivo levelFEBS Letters, 1991
- Effects of Tumor Necrosis Factor on Glomerular Mesangial and Epithelial Cells in CultureNephron, 1990